ERBB2 and breast cancer: In previous studies, we demonstrated that approximately 70% of ER+ mammary tumors are sensitive to the anti-proliferative effects of ATRA, while only 10–20% of the HER2+ and TNBC counterparts respond to the retinoid [9,10].